No Data
No Data
Buy Rating Affirmed for Equillium Amid Promising Clinical Trials and Potential Financial Upsides
Equillium Shares Fall After Swing to 4Q Loss
By Dean Seal Shares of Equillium fell after the company swung to a loss in the fourth quarter on lower sales. The stock was down 18% at $2 on Tuesday. Shares have more than doubled since the start o
VERI, CHEK and CZOO Among Mid-day Movers
Equillium: Q4 Earnings Insights
Equillium (NASDAQ:EQ) reported its Q4 earnings results on Monday, March 25, 2024 at 04:01 PM.Here's what investors need to know about the announcement.EarningsEquillium beat estimated earnings by 59.0
Equillium Swings to Q4 Loss As Revenue Falls
Equillium (EQ) reported a Q4 loss late Monday of $0.07 per diluted share, compared with net income of $0.08 a year earlier. Three analysts polled by Capital IQ expected a loss of $0.17. Revenue for th
Equillium Q4 2023 GAAP EPS $(0.07) Beats $(0.17) Estimate, Sales $9.200M Beat $6.425M Estimate
Equillium (NASDAQ:EQ) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.17) by 58.82 percent. The company reported quarterly sales of $9.200 million whic
No Data